Clinical Trials Directory

Trials / Completed

CompletedNCT02448472

Epidemiology of Sepsis in China

Chinese Epidemiological Study of Severe Sepsis.(CHESS Study)

Status
Completed
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
Jianfeng Xie · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Sepsis is a common cause for morbidity and mortality in critically ill patients. In USA, the incidence of sepsis is about 3/1000 population. However, the incidence of sepsis varies among different clinic trails. In addition, clinician empirical select antibiotic according to the epidemiology of sepsis, however, the etiology of sepsis is various in different studies. In China, the MDRO is much higher than western country. There is no study about the epidemiology of sepsis in China. Therefore, it is necessary to conduct a study about it in China.

Detailed description

Sepsis,especially severe sepsis is a major cause of admission to the intensive care unit (ICU) and death. In USA, the incidence of sepsis is about 3/1000 population. However, the incidence of sepsis varies among different clinic trails. Between 6 and 54% of patients admitted to ICUs have severe sepsis and the mortality rate for these patients varies from 20 to 60%. There is no exactly results of incidence of sepsis in China. In addition, clinician empirical select antibiotic according to the epidemiology of sepsis, however, the etiology of sepsis is various in different studies. In EPIC II study, the organisms of sepsis include Gram-positive microorganisms (69.8%),Gram-negative microorganisms(62.2%) and fungi (17%). In China, the MDRO is much higher than western country. In contrast to EPIC II study, one study in China showed that the organisms of sepsis include Gram-positive microorganisms (14.5%),Gram-negative microorganisms(62.5%) and fungi (2.2%). Therefore, it is necessary to conduct a study about epidemiology of sepsis in China.

Conditions

Interventions

TypeNameDescription
OTHERObservational study, none intervention

Timeline

Start date
2015-11-01
Primary completion
2015-12-01
Completion
2016-01-01
First posted
2015-05-19
Last updated
2016-02-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02448472. Inclusion in this directory is not an endorsement.